Abstract. Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic kidney disorders. Thiazolidinediones (TZDs) are anti-diabetic drugs that have been shown to suppress polycystic kidney diseases (PKD) development. However, their underlying mechanism of action remains largely unknown. Insulin-like growth factor-1 (IGF-1) expression increases with the progression of cystic lesions in ADPKD and murine PKD, thus the increased expression of IGF-1 may contribute to the progression of cystic lesions. p70S6 kinase (p70S6K) is an important downstream signaling molecule of IGF-1 and is implicated in the regulation of cell cycle progression and cell proliferation. In the present study, we found that IGF-1 increased the growth of cyst-lining epithelial cells by 15-20% in a dose-dependent manner, while no effect on the proliferation of normal renal cortical tubular epithelial cells (RCTEC) was observed. Rosiglitazone, a TZD, was found to inhibit the IGF-1-induced growth of cyst-lining epithelial cells when applied at a dose of 50-200 µM. However, the IGF-1-induced growth of immortalized epithelial cells from >30 individual renal cysts obtained from 11 ADPKD patients (WT9-12 cells) was inhibited with a 12.5-µM dose of rosiglitazone. Moreover, rosiglitazone (at the same concentration) was shown to inhibit the IGF-1-induced activation of p70S6K. TZDs are known to exert antitumor properties via peroxisome proliferator-activated receptor (PPAR)γ-dependent and -independent mechanisms. The present study showed that PPARγ small interfering RNA (siRNA) did not block the effect of rosiglitazone in inhibiting the IGF-1-induced phosphorylation of p70S6K. In conclusion, cyst-lining epithelial cells were found to be more sensitive to IGF-1 compared with normal cells. Rosiglitazone inhibited the proliferation of cyst-lining epithelial cells; more specifically, it inhibited the proliferation-promoting activity of IGF-1 in these cells. This effect of rosiglitazone was demonstrated to be partially due to the inhibition of IGF-1-induced activation of p70S6K. Increased IGF-1 expression was identified in early-stage PKD, indicating that rosiglitazone is more suitable for the treatment of early-stage PKD.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders worldwide, with a frequency of 1 in 1,000 in the general population. The excessive proliferation of renal tubular epithelial cells leads to cysts that eventually replace most of the normal tissue. Consequently, ADPKD results in severe enlargement of the kidneys, and renal failure occurs by the age of 50 in the majority of cases (1) (2) .
Insulin-like growth factor-1 (IGF-1) preferentially binds to IGF-1 and insulin receptors. The two receptors are structurally similar and a number of their downstream molecules are the same, including insulin receptor substrate-1 (IRS-1), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB/Akt), mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K), while their physiological functions are different. IGF-1 signaling favors cell growth, proliferation and survival in relation to nutrient availability (3) . IGF-1 has a well-documented role in cancer development in several tissues (4) , and its expression has been found to increase with the progression of cystic lesions in ADPKD and murine polycystic kidney diseases (PKDs) (5); therefore, IGF-1 may contribute to the progression of cystic lesions.
Thiazolidinediones (TZDs) are anti-diabetic drugs that improve insulin sensitivity in patients with type 2 diabetes since they are high-affinity ligands for peroxisome proliferator-activated receptor (PPAR)γ, a transcription factor that is highly expressed in adipose tissues. Although TZDs are only approved for the treatment of type 2 diabetes, they are also known to have additional potentially beneficial effects (6) . It has been shown that TZDs are capable of inhibiting cell proliferation and inducing apoptosis in a wide variety of tumor cell lines (7) . Recent studies have suggested that TZDs inhibit the progression of PKD (8) (9) (10) . However, the underlying mechanism of action of TZDs in PKD remains unknown.
The IGF-1/p70S6K pathway is activated in PKD, and rosiglitazone has been suggested to inhibit the expression of Rosiglitazone inhibits insulin-like growth factor-1-induced polycystic kidney disease cell growth and p70S6 kinase activation CHUNYAN (11) . The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml each of penicillin and streptomycin. The cells were seeded at a density of 4,000 cells/well in a 96-well plate. After 24 h, 10% FBS growth medium was replaced with serum-free medium. Cells were either treated with rosiglitazone or IGF-1, or the combination of both. Cell growth curves were determined 24, 48 and 72 h following treatment using a tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, MTT (500 µg/ml) was added to cells for 4 h. The cells were then collected using a DMSO solution. The rate of MTT uptake and the formation of blue formazan crystals by live cells were determined by absorption at a wavelength of 490 nm using an enzyme-linked immunosorbent assay (ELISA) reader (ELX 800; BioTek Intstruments, Winooski, VT, USA).
Western blot analysis.
For western blot analysis, the cells treated with various chemicals were washed with ice-cold phosphate-buffered saline (PBS) and lysed in RIPA buffer (1 mM phenylmethylsulfonyl fluoride, 10 mM β-glycerophosphate, 1 mM NaF and 1 mM Na 3 VO 4 ) containing protease inhibitor cocktail. Protein concentrations were determined using a BCA protein assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA). Equal amounts of protein (100 µg) were loaded and separated on SDS-polyacrylamide gels and then transferred to nitrocellulose membranes. After blocking, membranes were probed with antibodies against p70S6K, p-p70S6K-Thr 421/424 and PPARγ followed by the corresponding horseradish peroxidase (HRP)-conjugated secondary antibody. Positive staining was revealed via a reaction with an enhanced chemiluminescence (ECL) reagent and development on an X-ray film.
Transfection with small interfering RNAs (siRNAs).
PPARγ and non-specific control siRNAs were purchased from Cell Signaling Technology, Inc. For the transfection, the cells were grown until 30-40% confluence, and PPARγ or non-specific control siRNAs were introduced into the cells using the Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA, CA) according to the manufacturer's instructions. Briefly, Lipofectamine reagent and siRNA were diluted in a serum-free medium. After 5 min, the two solutions were mixed and placed at room temperature for an additional 20 min. The mixture was then added to the cells. The final concentration of siRNA in each well was 100 nM. A number of cells were treated with rosiglitazone (50 µM) 48 h after the transfection, and then cell lysates were collected for western blot analysis 24 h after this treatment.
Statistical analysis.
All the experiments were repeated at least three times. Data were expressed as the mean ± SD. Statistical significance was determined with Student's t-test (two-tailed) for comparisons between two groups. P<0.05 was considered to indicate a statistically significant difference.
Results

IGF-1 increases the proliferation of cyst-lining epithelial cells.
The growth of the cyst-lining epithelial cell line WT9-12 was compared with that of a normal cell line (RCTEC) to investigate the effect of IGF-1 on cell proliferation. The effect of IGF-1 on cell growth was examined by treating the cells with various concentrations of IGF-1 (5-200 ng/ml). The rate of cell growth was determined 72 h following treatment using an MTT assay. IGF-1 treatment was found to increase WT9-12 cell growth by 15-20% in a dose-dependent manner, while it had no effect on RCTEC cell proliferation (Fig. 1) .
Rosiglitazone inhibits IGF-1-induced PKD cell growth. The effect of rosiglitazone or rosiglitazone combined with IGF-1 on cell growth was examined in order to investigate the effect of rosiglitazone on IGF-1-induced PKD cell growth. Rosiglitazone at doses of 50-200 µM was found to inhibit WT9-12 cell proliferation in a dose-dependent manner (Fig. 2) . However, IGF-1-induced WT9-12 cell proliferation was inhibited with a 12.5-µM dose of rosiglitazone (Fig. 3) .
Rosiglitazone inhibits IGF-1-induced phosphorylation of p70S6K in a PPARγ-independent manner.
The p70S6K signaling molecule is involved in the regulation of cell cycle progression and cell proliferation (12) . We found that IGF-1 increased the phosphorylation of p70S6K in a dose-and time-dependent manner in WT9-12 cells (Figs. 4 and 5) . The expression of p-P70S6K was increased after WT9-12 cells were treated with IGF-1 (20 ng/ml) for 2 h.
Rosiglitazone was found to inhibit IGF-1-induced phosphorylation of p70S6K (Fig. 6 ). Rosiglitazone, a synthetic ligand for PPARγ, inhibits cell growth through PPARγ-dependent and -independent signaling pathways (19) . Therefore, we investigated whether the effect of rosiglitazone on IGF-1-induced phosphorylation of p70S6K was mediated by the activation of PPARγ. WT9-12 cells were transfected with PPARγ or control siRNA. The cells were then treated with IGF-1 or rosiglitazone, or the combination of both. As shown in Fig. 6 , the effect of rosiglitazone on IGF-1-induced p70S6K phosphorylation was unable to be blocked. This suggests that rosiglitazone may inhibit IGF-1-induced phosphorylation of p70S6K in a PPARγ-independent manner.
Discussion
One of the main changes in the PKD kidney is an increase in the proliferative activity of cyst-lining epithelial cells. Proliferating cells are frequently detected in normal tubular segments and are relatively sparse in large cysts. These findings suggest that the increase in proliferative activity is an early event and may predispose these cells to the acquisition of a cystic phenotype (13, 14) .
IGF-1 is a multifunctional hormone that has pleiotropic effects on cellular proliferation, apoptosis, hypertrophy, senescence and differentiation. Multiple lines of evidence suggest that IGF-1 plays a role in mediating tubular cell proliferation in the cystic kidney, particularly during the early stages of PKD. The present and previous studies have found that IGF-1 induces PKD cell proliferation, while no effect has been observed in normal tubular cells (15) . This indicates that PKD cells are more sensitive to IGF-1 compared with normal cells.
Rosiglitazone is effective in regulating cell activation, differentiation, proliferation and/or apoptosis (16) . The efficacy of this compound as an anticancer agent has been examined in a variety of cancers, including colon, breast, prostate and non-small cell lung carcinoma (6, 17) . In polycystic renal disease, rosiglitazone has been suggested to inhibit the progression of PKD (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In the present study, we showed that rosiglitazone inhibited the proliferation of PKD cells and that it had a more predominant inhibiting effect on IGF-1-induced cell proliferation. This finding indicates that rosiglitazone is suitable for the treatment of early-stage PKD.
p70S6K is an important downstream signaling molecule of IGF-1. The activity of p70S6K, which is determined by the phosphorylation of p70S6K, is enhanced in the kidneys of ADPKD patients and is important in the pathogenesis of ADPKD (19) . In the present study, we found that IGF-1 induced the phosphorylation of p70S6K in PKD cells, while rosiglitazone inhibited the effect of IGF-1 on p70S6K phosphorylation. TZDs are known to act in a PPARγ-dependent and -independent manner (19) . Our study indicated that rosiglitazone inhibited IGF-1-induced phosphorylation of p70S6K through a PPARγ-independent manner.
In summary, we found that rosiglitazone inhibited the IGF-1-induced activation of p70S6K via a PPARγ-independent mechanism. This appears to account for, at least in part, the mechanism by which rosiglitazone inhibits IGF-1-induced PKD cell proliferation. IGF-1 has an important effect on early-stage PKD; therefore, rosiglitazone is suggested to be more effective in the treatment of early-stage PKD.
